Metabolic-Associated Fatty Liver Disease in Childhood and Adolescence

References

1. • Zhang X.
   • Wu M.
   • Liu Z.
   • et al.
   Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: A population-based observational study.
   BMJ Open. 2021; 11: e042843
   View in Article

   • Google Scholar

2. Obesity and overweight. World Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed January 28, 2023.

   View in Article

   • Google Scholar
3. • Obita G.
   • Alkhatib A.
   Disparities in the Prevalence of Childhood Obesity-Related Comorbidities: A Systematic Review.
   Front Public Health. 2022; 10https://doi.org/10.3389/fpubh.2022.923744
   View in Article

   • Google Scholar
4. • Yi M.
   • Peng W.
   • Feng X.
   • et al.
   Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta-analyses.
   Aliment Pharmacol Ther. 2022 Oct; 56: 1119-1130
   View in Article

   • Google Scholar
5. • Anderson E.L.
   • Howe L.D.
   • Jones H.E.
   • et al.
   The prevalence of non-alcoholic fatty liver disease in children and adolescents: A systematic review and meta-analysis.
   PLoS One. 2015; 10
   View in Article

   • Google Scholar
6. • Castillo-Leon E.
   • Cioffi C.E.
   • Vos M.B.
   Perspectives on youth-onset nonalcoholic fatty liver disease.
   Endocrinol Diabetes Metab. 2020; 3https://doi.org/10.1002/edm2.184
   View in Article

   • Google Scholar
7. • Younossi Z.M.
   • Koenig A.B.
   • Abdelatif D.
   • et al.
   Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes.
   Hepatology. 2016 Jul; 64: 73-84
   View in Article

   • Google Scholar
8. • Hirode G.
   • Saab S.
   • Wong R.J.
   Trends in the Burden of Chronic Liver Disease among Hospitalized US Adults.
   JAMA Netw Open. 2020; 3https://doi.org/10.1001/jamanetworkopen.2020.1997
   View in Article

   • Google Scholar
9. • Fang Y.L.
   • Chen H.
   • Wang C.L.
   • et al.
   Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model.
   World J Gastroenterol. 2018; 24: 2974-2983
   View in Article

   • Google Scholar
10. • Dowman J.K.
    • Tomlinson J.W.
    • Newsome P.N.
    Pathogenesis of non-alcoholic fatty liver disease.
    QJM. 2009; 103: 71-83
    View in Article

    • Google Scholar
11. • Marzuillo P.
    • Grandone A.
    • Perrone L.
    • et al.
    Understanding the pathophysiological mechanisms in the pediatric non-alcoholic fatty liver disease: The role of genetics.
    World J Hepatol. 2015; 7: 1439-1443
    View in Article

    • Google Scholar
12. • Dongiovanni P.
    • Donati B.
    • Fares R.
    • et al.
    PNPLA3 I148M polymorphism and progressive liver disease.
    World J Gastroenterol. 2013; 19: 6969-6978
    View in Article

    • Google Scholar
13. • Draijer L.
    • Benninga M.
    • Koot B.
    Pediatric NAFLD: an overview and recent developments in diagnostics and treatment.
    Expert Rev Gastroenterol Hepatol. 2019; 13: 447-461
    View in Article

    • Google Scholar
14. • Santoro N.
    • Kursawe R.
    • D’Adamo E.
    • et al.
    A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents.
    Hepatology. 2010; 52: 1281-1290
    View in Article

    • Google Scholar
15. • Nobili V.
    • Alisi A.
    • Valenti L.
    • et al.
    NAFLD in children: new genes, new diagnostic modalities and new drugs.
    Nat Rev Gastroenterol Hepatol. 2019; 16: 517-530
    View in Article

    • Google Scholar
16. • Marzuillo P.
    • Grandone A.
    • Conte M.
    • et al.
    Novel association between a nonsynonymous variant (R270H) of the G-protein-coupled receptor 120 and liver injury in children and adolescents with obesity.
    J Pediatr Gastroenterol Nutr. 2014; 59: 472-475
    View in Article

    • Google Scholar
17. • Oh D.Y.
    • Talukdar S.
    • Bae E.J.
    • et al.
    GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects.
    Cell. 2010; 142: 687-698
    View in Article

    • Google Scholar
18. • Phen C.
    • Ramirez C.M.
    Hepatic Steatosis in the Pediatric Population: An Overview of Pathophysiology, Genetics, and Diagnostic Workup.
    Clin Liver Dis. 2021; 17: 191-195
    View in Article

    • Google Scholar
19. • Xue R.
    • Su L.
    • Lai S.
    • et al.
    Bile acid receptors and the gut–liver axis in nonalcoholic fatty liver disease.
    Cells. 2021; 10https://doi.org/10.3390/cells10112806
    View in Article

    • Google Scholar
20. • Carter-Kent C.
    • Yerian L.M.
    • Brunt E.M.
    • et al.
    Nonalcoholic steatohepatitis in children: A multicenter clinicopathological study.
    Hepatology. 2009; 50: 1113-1120
    View in Article

    • Google Scholar
21. • Schwimmer J.B.
    • Behling C.
    • Newbury R.
    • et al.
    Histopathology of pediatric nonalcoholic fatty liver disease.
    Hepatology. 2005; 42: 641-649
    View in Article

    • Google Scholar
22. • Mann J.P.
    • Valenti L.
    • Scorletti E.
    • et al.
    Nonalcoholic Fatty Liver Disease in Children.
    Semin Liver Dis. 2018; 38: 1-13
    View in Article

    • Google Scholar
23. • Vos M.B.
    • Abrams S.H.
    • Barlow S.E.
    • et al.
    NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).
    J Pediatr Gastroenterol Nutr. 2017; 64: 319-334
    View in Article

    • Google Scholar
24. • Ovchinsky N.
    • Moreira R.K.
    • Lefkowitch J.H.
    • et al.
    Liver Biopsy in Modern Clinical Practice: A Pediatric Point-of-View.
    (Available at:)
    http://www.anatomic

    Date: 2012
    View in Article

    • Google Scholar
25. • Cusi K.
    • Isaacs S.
    • Barb D.
    • et al.
    American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).
    Endocr Pract. 2022; 28: 528-562
    View in Article

    • Google Scholar
26. • Castera L.
    • Friedrich-Rust M.
    • Loomba R.
    Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
    Gastroenterology. 2019; 156: 1264-1281.e4
    View in Article

    • Google Scholar
27. • Chen B.R.
    • Pan C.Q.
    Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2022; 46https://doi.org/10.1016/j.clinre.2021.101755
    View in Article

    • Google Scholar
28. • Shannon A.
    • Alkhouri N.
    • Carter-Kent C.
    • et al.
    Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD.
    J Pediatr Gastroenterol Nutr. 2011; 53: 190-195
    View in Article

    • Google Scholar
29. • Vajro P.
    • Lenta S.
    • Socha P.
    • et al.
    Diagnosis of nonalcoholic fatty liver disease in children and adolescents: Position paper of the ESPGHAN hepatology committee.
    J Pediatr Gastroenterol Nutr. 2012; 54: 700-713
    View in Article

    • Google Scholar
30. • Lin S.C.
    • Heba E.
    • Wolfson T.
    • et al.
    Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique.
    Clin Gastroenterol Hepatol. 2015; 13: 1337-1345.e6
    View in Article

    • Google Scholar
31. • Shin N.Y.
    • Kim M.J.
    • Lee M.J.
    • et al.
    Transient elastography and sonography for prediction of liver fibrosis in infants with biliary atresia.
    J Ultrasound Med. 2014; 33: 853-864
    View in Article

    • Google Scholar
32. • Desai N.K.
    • Harney S.
    • Raza R.
    • et al.
    Comparison of controlled attenuation parameter and liver biopsy to assess hepatic steatosis in pediatric patients.
    J Pediatr. 2016; 173: 160-164.e1
    View in Article

    • Google Scholar
33. • Xanthakos S.A.
    • Podberesky D.J.
    • Serai S.D.
    • et al.
    Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease.
    J Pediatr. 2014; 164: 186-188
    View in Article

    • Google Scholar
34. • Friesen C.S.
    • Hosey-Cojocari C.
    • Chan S.S.
    • et al.
    Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy.
    Front Endocrinol. 2021; 12https://doi.org/10.3389/fendo.2021.663351
    View in Article

    • Google Scholar
35. • Ebbeling C.B.
    • Feldman H.A.
    • Chomitz V.R.
    • et al.
    A Randomized Trial of Sugar-Sweetened Beverages and Adolescent Body Weight.
    N Engl J Med. 2012; 367: 1407-1416
    View in Article

    • Google Scholar
36. • de Ruyter J.C.
    • Olthof M.R.
    • Seidell J.C.
    • et al.
    A Trial of Sugar-free or Sugar-Sweetened Beverages and Body Weight in Children.
    N Engl J Med. 2012; 367: 1397-1406
    View in Article

    • Google Scholar
37. • Taskinen M.R.
    • Packard C.J.
    • Borén J.
    Dietary fructose and the metabolic syndrome.
    Nutrients. 2019; 11https://doi.org/10.3390/nu11091987
    View in Article

    • Google Scholar
38. • Ryan M.C.
    • Itsiopoulos C.
    • Thodis T.
    • et al.
    The Mediterranean Diet Improves Hepatic Steatosis and Insulin Sensitivity in Individuals with Non-Alcoholic Fatty Liver Disease.
    J Hepatol. 2013; 59: 138-143
    View in Article

    • Google Scholar
39. • Lavine J.E.
    • Schwimmer J.B.
    • van Natta M.L.
    • et al.
    Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents The TONIC Randomized Controlled Trial.
    JAMA. 2011; 305 (Available at:): 1659-1668
    https://jamanetwork.com/
    View in Article

    • Google Scholar
40. • Crudele A.
    • Panera N.
    • Braghini M.R.
    • et al.
    The pharmacological treatment of nonalcoholic fatty liver disease in children.
    Expert Rev Clin Pharmacol. 2020; 13: 1219-1227
    View in Article

    • Google Scholar
41. • Francque S.M.
    • Bedossa P.
    • Ratziu V.
    • et al.
    A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
    N Engl J Med. 2021; 385: 1547-1558
    View in Article

    • Google Scholar
42. • Harrison S.A.
    • Wong V.W.S.
    • Okanoue T.
    • et al.
    Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
    J Hepatol. 2020; 73: 26-39
    View in Article

    • Google Scholar
43. • Attia S.L.
    • Softic S.
    • Mouzaki M.
    Evolving Role for Pharmacotherapy in NAFLD/NASH.
    Clin Transl Sci. 2021; 14: 11-19
    View in Article

    • Google Scholar
44. • Younossi Z.M.
    • Ratziu V.
    • Loomba R.
    • et al.
    Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
    Lancet. 2019; 394: 2184-2196
    View in Article

    • Google Scholar
45. • Ratziu V.
    • de Guevara L.
    • Safadi R.
    • et al.
    Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial.
    Nat Med. 2021; 27: 1825-1835
    View in Article

    • Google Scholar
46. • Kelly A.S.
    • Auerbach P.
    • Barrientos-Perez M.
    • et al.
    A randomized, controlled trial of liraglutide for adolescents with obesity.
    N Engl J Med. 2020; 382: 2117-2128
    View in Article

    • Google Scholar